Study on the Therapeutic Effect and Mechanism of Yinaokang on Post-stroke Cognitive Impairment No Dementia

Phase 1

• Conditions: post-stroke cognitive impairment no dementia

• Registration Number: ITMCTR2000004178
• Lead Sponsor: GuangDong Provincial Hospital of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) From 50 to 85 years old, male or female, receive education above the primary school;
(2) Meet the PSCIND diagnostic criteria;
(3) Neuroimaging(CT or MRI) supports the diagnosis of cerebrovascular diseases;
(4) Patients can move freely by himself or with the aid of a caregiver;
(5) Good audio-visual function ensuring cooperation with the examination and treatment;
(6) The subjects are voluntary and have signed informed consent.

Exclusion Criteria

(1) Diagnosis of Dementia, or cognitive impairment caused by other causes except for stroke;
(2) Delirium, depression, or other neurological disorders;
(3) Have severe comorbidity such as the severe liver and kidney dysfunction, or severe heart failure, etc.;
(4) Use other medications or therapies that may affect cognitive function;
(5) Participate in other clinical studies within the last three months;
(6) Meet the contraindications of experimental medicines or allergic to experimental medicines.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Montreal Cognitive Assessment, MOCA;

Secondary Outcome Measures

Name	Time	Method
Activity of Daily Living, ADL;inflammatory cytokines;Vitamin D;homocysteine;Parathyroid hormone;Mini Mental State Examination Scale (MMSE);